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Objectives. This paper focuses on current diagnostic and treatment options for Eosinophilic Esophagitis (EE). Study Design.l i t e r a -
turereview. Results.EEcanbesuspectedonhistoryandendoscopyalthoughdeﬁnitivediagnosisisstrictlybasedonhistopathology.
Itisarelativelynewentityandisoftenmisdiagnosedasgastroesophagealreﬂux(GERD).Eosinophilicinﬁltrationoftheesophageal
mucosa is responsible for esophageal symptoms which can range from mild to debilitating dysphagia and food impaction, when
untreated. In fact recurrent foreign body and food impaction can often be blamed for undiagnosed EE. There seems to be a strong
familial component and association with allergy. The introduction of transnasal esophagoscopy in adult laryngology has enabled
otolaryngologists to readily diagnose EE and promoted awareness of this often diﬃcult to recognize entity. Conclusions. Despite
higher awareness, the literature suggests that EE remains a commonly misdiagnosed condition especially in the otolaryngology
community. Genetic studies are required to unfold the true familial and genetic component of this fascinating entity.
1.Introduction
Eosinophilic esophagitis (EE) previously known as idiopath-
ic eosinophilic oesophagitis, atopic oesophagitis, and allergic
oesophagitis is a clinicopathological entity that is being diag-
nosed with increasing frequency. According to the latest con-
sensus EE represents a chronic immune/antigen-mediated
esophageal disease characterized clinically by symptoms re-
lated to esophageal dysfunction and histologically by eosin-
ophil-predominantinﬂammation[1].Thisdiseaseisisolated
totheesophagusandhastobedistinguishedofanymoderate
eosinophilic inﬁltration associated to a generalized eosino-
philicinﬁltrationofagutmucosa(gastroenteritisandcolitis)
[1]. The diagnostic criteria of EE include esophageal and/or
upper gastrointestinal tract symptoms accompanied by ≥15
intraepithelial eosinophils/high power ﬁeld (HPF) in 1 or
more biopsy specimens without pathologic gastroesophageal
reﬂux disease (GERD), as shown by normal pH monitoring
of the distal esophagus or the lack of response to high-dose
proton pump inhibitor (PPI) medication [2].
2. Epidemiology
EE was thought to be a rare condition; however a sharp rise
in its prevalence is recognized in most countries. This could
be due to a combination of a true escalation in its incidence,
combined with an increasing recognition, awareness, and
testing amongst gastroenterologists, otolaryngologists, and
pathologists. This notion is supported by the fact that there
are numerous reports of patients with multiple oesophageal
rings with intraepithelial eosinophils that had been ascribed
to acid reﬂux, but who did not respond to standard acid
suppression therapy. In retrospect, these patients may have
had EE [3–5].
The literature reveals an increase in frequency in both
pediatric[6]andadult[7]populations.Oneparticularnorth
American study showed that the incidence of EE has in-
creaseddramaticallyfrom0.35per100000between1991and
1995 to 9.45 per 100000 between 2001 and 2005 making the
prevalence of EE 55.0 per 100,000 people [8].
EE aﬀects both sexes and all age groups with the typical
patient being an atopic male presenting in childhood or the
3rd or 4th decades of life [1]. The age at diagnosis can vary
though. The disease aﬀects 8 children and one adult, and
most pediatric cases appear in the ﬁrst three years [1, 3].
Moreover, children with eosinophilic esophagitis have a
higher frequency of atopic symptoms and peripheral eosin-
ophilia than do adults [7]. The male-to-female prevalence
ratiohasbeenreportedas3:1withcasesextensivelyreported2 International Journal of Otolaryngology
inpatientsofdiﬀerentethnicorigins[3].Familialtrendshave
been reported [9–12] with the majority of cases to date re-
portedfromNorthAmericaandEuropeandtoalesserextent
Asia, Australia, and South America. No cases have been re-
ported from Africa [10].
3.Etiology
There are a number of factors that are believed to play a role
in the origin of EE. These are genetics, allergy, seasonal vari-
ation, and GERD.
T h e r ei sm o r el i t e r a t u r et os u p p o r tag e n e t i cb a s i sf o r
EE. Studies have validated the expression of a unique EE
transcriptome and validated that it diﬀerentiates EE from
GERD,witheotaxin-3beingabundantlyoverexpressedinpa-
tients with EE [1, 13]. IL-13 has been found to be speciﬁcally
upregulated in the esophagi of patients with EE and might
function as a master regulator of the EE transcriptome [14].
Rothenberg et al. have identiﬁed the ﬁrst genome-wide
susceptibility locus at 5q22 [15]. Sherrill et al. have reported
that polymorphisms in the thymic stromal lymphopoietin
(TSLP) gene are risk factors for EE independent of under-
lying allergy phenotypes [16]. They state there is a gender-
speciﬁc association between single-nucleotide polymorph-
isms (SNPs) in TSLP as well as a nonsynonymous SNP in
the TSLP receptor which suggests a mechanism for the male
predilection of the EoE [16]. Another SNP in the promoter
of the TGF-β1 gene has been linked to reduced esophageal
remodeling following topical steroid treatment. Familiar
cases have also been reported [17].
More studies are supporting the concept that EE is an
antigen-driven allergic condition, with a varying percentage
of pediatric and adult patients having at least one more
“allergic” disease. It is reported that 50%–60% of patients
with EE have a prior history of atopy [1, 8, 18]. The majority
of patients have evidence of or a familiar history of allergic
rhinitis, asthma, eczema, or hypersensitivity to foods or ae-
roallergens. The latter two are based on skin prick testing
and IgE test results. Moawad et al. demonstrated a seasonal
variation in the diagnosis of EE which correlated with higher
pollen count [19]. However, EE was still present during
periods of lower atmospheric pollen concentrations and in
patients without a history of atopic disease, pointing towards
a possible multifactorial pathogenesis. In the pediatric litera-
ture, food allergies have been implicated in the pathogenesis
of EE [19, 20].
Allergens induce T-helper-2 (Th2) cells to produce in-
terleukin (IL)-13, which can cause esophageal cells to over-
express eotaxin-3 and ﬁbroblasts. Activated Th2 cells also
produce IL-5, which regulates eosinophil numbers and their
response to eotaxin-3. In addition to eosinophils, mast
cells and lymphocytes (including B cells) accumulate in the
esophagus to contribute to the local inﬂammatory responses
observed in patients with EE. The resulting injury leads to
esophageal remodelling with wallthickening and ﬁbrosis [9].
The cytotoxic role of eosinophils in EE is directly related
to the observed histopathological changes with destruction
of the most superﬁcial epithelial layers and the regenerative
response from the basal layers of the epithelium [21, 22].
The exact role of GERD in the development of EE is un-
clear; however the latest updated consensus recommenda-
tions states esophageal pH monitoring is useful to establish
whether GERD is present in EE or not [1].
4. ClinicalPresentation
Clinical manifestations in children are less speciﬁc, whereas
in adults they are more predictable. Feeding diﬃculties are
the manifestation in infants and toddlers, whereas vomiting
and/or pain may be present in school-aged children. Dys-
phagia is the main symptom in adolescents [1, 5]. Other
symptoms include a failure to thrive, heartburn, and isolated
nausea [9]. To date, no pathognomonic features have been
identiﬁed. Atopy is a common association in pediatric and
adult patients with evidence of another allergic disease (al-
lergic rhinitis, asthma, eczema, or hypersensitivity to foods
or aeroallergens) in more than half the cases. Family history
of atopy is frequent, with one study reporting a rate of 74%
[9, 23].
The most common presenting symptom in adults is solid
food dysphagia. Others include food impaction (which may
or may not require endoscopic intervention), chest and up-
per abdominal discomfort/pain, and resistant reﬂux symp-
toms (despite a trial of acid suppression). One study showed
that more than half of patients with esophageal food impac-
tion, based on clinicopathologic features are likely to have EE
[24].
There is a subset of patients who have symptoms of EE,
have had GERD diagnostically excluded but still demon-
strate a clinicopathologic response to PPIs. Terms used to
describe these patients include PPI-responsive esophageal
eosinophilia. The deﬁnition and diagnostic guidelines of EE
include the term immune/antigen driven; however, studies
and clinical experience have identiﬁed a potential anti-
inﬂammatory or “barrier healing” role for proton pump in-
hibition in patients with esophageal eosinophilia [1].
5.Diagnosis
Esophagoscopy with biopsy is the ideal investigation for
the diagnosis of EE. There are various endoscopic ﬁndings,
however none pathognomonic for EE. These include mu-
cosal fragility (59% of cases), esophageal “trachealization”
(multiple concentric rings resembling the trachea) in 49%,
strictures in 40% of cases, furrows, white plaques, or papules
in 16% (aggregates of eosinophilic microabscesses), irregular
mucosa, reddish changes in esophageal mucosal pattern,
esophageal tears, and a narrow caliber in 5% [10]. Many of
these features, including longitudinal furrows, are subtle and
can be missed. Between 9% and 32% of patients with symp-
toms suggesting eosinophilic esophagitis have normal endo-
scopic ﬁndings, and studies have shown patients can have
histologically proven EE yet normal macroscopic appearance
on endoscopy [25].
Radiological investigations are not recommended except
in selected cases in order to elicit anatomical abnormali-
ties/variations.International Journal of Otolaryngology 3
Histology is essential in making the diagnosis of EE. The
latest consensus recommends that 2 to 4 mucosal biopsy
specimens of the proximal and distal esophagus should be
obtained, as various studies have shown the eosinophilic
inﬁltration is similar in these sections of the esophagus. In
children and, when indicated in adults, biopsy specimens of
the gastric antrum and duodenum should be obtained once
to exclude other potential causes of esophageal eosinophilia
[1]. No prospective studies have determined a threshold
number of esophageal eosinophils that can establish a di-
agnosis of EE with high speciﬁcity and sensitivity and con-
sistently allow diﬀerentiation of EE from other causes of
esophageal eosinophilia. It is recommended that, until more
studies are performed, all histologic features including eos-
inophil microabscess formation, superﬁcial layering of eos-
inophils, extracellular eosinophil granules, basal cell hyper-
plasia, dilated intercellular spaces, rete peg elongation, sub-
epithelial lamina propria ﬁbrosis, and increases in other cell
t y p e sb en o t e di np a t h o l o g yr e p o r t s[ 1].
One-third to one-half of patients have peripheral eos-
inophilia, and up to 55% have increased serum levels of im-
munoglobulinE(IgE),thereforethesearchforspeciﬁcIgEsis
strongly advised [20]. Although peripheral eosinophilia can
correlate with tissue eosinophilia in some patients with EE,
changesintheformerneedtobeconsideredwithcaution[1].
Because of the association with allergic diseases, a complete
evaluationofaeroallergenandimmediatetypefoodallergyis
warranted.
6. Treatment
Management of patients EE remains controversial. EE is a
chronic disease and its activity may ﬂuctuate independently
of any therapeutic intervention, and, although it aﬀects qual-
ity of life, it does not seem to limit life expectancy or be
associated with malignant or premalignant conditions. Sev-
eral treatment modalities have been tested. We focus on
medical, dietary, and surgical interventions according to the
2011 recommendation [1], which have recently replaced the
2007 recommendations.
Surgical intervention is usually reserved for the compli-
cations of EE, namely, stenosis of the esophagus. Esophageal
dilation with either Savary dilators or unsedated transnasal
balloon techniques is associated with an 83% symptom re-
sponse rate and a low complication rate of 5% [26]. Other
smaller studies report excellent symptomatic relief, for both
adults and children [27, 28]. Although dilation does not
improve the underlying inﬂammatory process and will prob-
ably need to be repeated, perhaps it is an adequate strategy
for the healthy, young to middle-aged men commonly af-
fected by the disease, who might prefer it to regular medica-
tions or diet [29]. Although complications are more frequent
than those associated with dilation for other benign condi-
tions [30], the risk of perforation appears to have been exag-
gerated—a systematic review of 18 studies [31] identiﬁed 1
perforation in 671 dilations (0.1% risk).
Medical treatment for EE needs to be both eﬀective and
safe, considering the fact that EE is a chronic disease requir-
ing prolonged courses of therapy for remission. Medications
used include corticosteroids, cromolyn sodium, proton-
pump inhibitors (PPIs), leukotriene receptor antagonists,
immunosuppressive agents, and monoclonal antibodies.
PPIs are used both for diagnostic and therapeutic pur-
poses. Acid suppression is important to rule out secondary
esophageal eosinophilia due to GERD, although some au-
thors feel EE’s contribution to refractory GERD is not sig-
nificant [32]. A high PPI dose of 20–40mg twice daily is
recommended for 8 to 12 weeks in adults (1mg/kg twice
daily in children with the adult dose as maximum). PPI
therapy alone is not eﬀective for patients with EE; however
it might alleviate symptoms related to secondary GERD
[1]. It has been suggested that PPI-responsive esophageal
eosinophilia is a diﬀerent clinical entity. A small randomized
controlledtrialcomparingPPIsversustopicalcorticosteroids
failed to show a diﬀerence between the groups [33].
Topical corticosteroids are eﬀective in children and
adults, inducing remission in most cases. A number of ran-
domized controlled trials have evaluated this in recent years:
a 15-day course of treatment with budesonide (viscous sus-
pension, 1mg twice daily for adults, 0.5mg twice daily for
children under 10 years old) is well tolerated and highly
eﬀective in inducing a histologic and clinical remission [1].
Fluticasone (440–880mg twice daily for adults, 88–440mg
twice to 4 times daily for children, puﬀed and swallowed
through a metered-dose inhaler) has also been used in adults
and children and was favoured before 2007 [33]. There is
no signiﬁcant evidence that either treatment is superior to
the other [1]. Systemic corticoids are not recommended due
to their adverse eﬀects (up to 40%) as other treatments are
almost equally eﬀective [33]. For severe urgent cases requir-
ing hospitalization, Prednisone 1-2mg/kg should be consid-
ered [1].
Other treatment modalities [1, 33] include
(a) cromolyn sodium, which was shown to be ineﬀective
and is not recommended,
(b) leukotriene receptor antagonists, of which mon-
telukast might have a role in maintaining remission
in children but was proven ineﬃcient in adults and is
not recommended,
(c) immune suppressants, such as azathioprine or 6-
mercaptopurine, which were shown to be ineﬀective
and is not recommended
(d) monoclonal antibodies, such as Mepolizumab, a hu-
manized monoclonal antibody against interleukin-5
(IL-5) which is not eﬀective in adults and although it
promotes a histologic response it is not clinically ef-
fective in children, Omalizumab (a monoclonal anti-
IgE antibody) which is not eﬀective [34], and Inﬂix-
imab (a chimeric monoclonal anti tumor necrosis
factor-α antibody) which is not eﬀective.
Diet modiﬁcation (elimination of speciﬁc foods guided
by skin prick and atopy patch testing) is eﬀective in over
75% of patients and should be attempted in children. In
adultsresultsaremixed,possiblybecauseofpoorcompliance
[1]. Elemental diet is not a real option in adults and elim-
ination diets (directed, or empirical of milk, egg, soy, peanut,4 International Journal of Otolaryngology
tree nut, wheat, shellﬁsh, and ﬁsh) do not achieve consistent
results.
7. Conclusions
Despite higher awareness, the literature suggests that EE
remains a commonly misdiagnosed condition especially in
the otolaryngology community. The introduction of Tran-
snasal Esophagoscopy in the ENT oﬃce over the last decade
has meant that increasingly more and more laryngologists
become accustomed in recognising esophageal pathology in-
cluding EE.
Genetic studies are required to unfold the true familial
and genetic component of this fascinating entity.
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